Largest pharmaceuticals by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 35 pharmaceuticals ranked by total debt, at AED 247.9B, ahead of Pfizer (AED 238B) and Merck & Co (AED 181.1B). Figures as of 18 Nov 2026, 14:43 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 35
- First
- AbbVieAED 247.9B
- Median
- AED 19.4B
- Combined market value
- AED 18.91T
- Countries
- 10
- Not ranked
- 26no total debt on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | AED 247.9B | AED 1.89T | AED 1,071.29 | 0.39% down | 26% up | ||
| 2 | PfizerPFE · Health Care | AED 238B | AED 596.1B | AED 104.57 | 0.05% up | 14% up | ||
| 3 | Merck & CoMRK · Health Care | AED 181.1B | AED 1.28T | AED 518.06 | 1.63% down | 51% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | AED 176.1B | AED 2.46T | AED 1,022.15 | 0.18% down | 38% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | AED 165.7B | AED 457.7B | AED 223.91 | 0.67% down | 34% up | ||
| 6 | Eli LillyLLY · Health Care | AED 156.1B | AED 4.63T | AED 5,200.59 | 0.05% up | 35% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | AED 112.3B | AED 253.3B | AED 79.29 | 0.25% down | 54% up | ||
| 8 | AstraZenecaAZN · Health Care | AED 108.8B | AED 1.03T | AED 665.05 | 0.62% down | 2% up | ||
| 9 | NovartisNVS · Health Care | AED 105.5B | AED 1.09T | AED 579.28 | 0.90% down | 25% up | ||
| 10 | SanofiSNY · Health Care | AED 76.2B | AED 420.2B | AED 174.99 | 0.25% up | 4% down | ||
| 11 | Novo NordiskNVO · Health Care | AED 71.4B | AED 652.9B | AED 148.15 | 0.90% down | 17% down | ||
| 12 | GSKGSK · Health Care | AED 70.5B | AED 363.5B | AED 181.35 | 0.31% up | 6% up | ||
| 13 | ViatrisVTRS · Health Care | AED 52.9B | AED 86.9B | AED 75.80 | 0.93% up | 96% up | ||
| 14 | Abbott LaboratoriesABT · Health Care | AED 47.5B | AED 671B | AED 387.45 | 0.71% up | 17% down | ||
| 15 | ZoetisZTS · Health Care | AED 33.2B | AED 125.4B | AED 308.69 | 0.69% up | 29% down | ||
| 16 | Royalty PharmaRPRX · Health Care | AED 32.9B | AED 145.8B | AED 253.57 | 0.53% up | 78% up | ||
| 17 | Jazz PharmaceuticalsJAZZ · Health Care | AED 19.7B | AED 57B | AED 888.29 | 0.48% up | 37% up | ||
| 18 | GenmabGMAB · Health Care | AED 19.4B | AED 117.6B | AED 190.68 | 0.08% down | 70% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | AED 14.8B | AED 48.2B | AED 96.51 | 1.66% up | 20% up | ||
| 20 | Amneal PharmaceuticalsAMRX · Health Care | AED 9.4B | AED 27.4B | AED 78.63 | 1.37% up | 83% up | ||
| 21 | BridgeBio PharmaBBIO · Health Care | AED 7.4B | AED 55.2B | AED 283.22 | 0.42% up | 17% up | ||
| 22 | Regeneron PharmaceuticalsREGN · Health Care | AED 7.3B | AED 367.1B | AED 3,549.12 | 0.90% up | 36% up | ||
| 23 | Ionis PharmaceuticalsIONS · Health Care | AED 6.7B | AED 16.7B | AED 100.26 | 1.26% up | 64% down | ||
| 24 | BeOne MedicinesONC · Health Care | AED 3.8B | AED 171.2B | AED 1,498.93 | 1.24% down | 17% up | ||
| 25 | Ascendis PharmaASND · Health Care | AED 2.9B | AED 65B | AED 991.54 | 0.44% down | 28% up | ||
| 26 | InsmedINSM · Health Care | AED 2B | AED 97.9B | AED 446.25 | 0.29% down | 40% down | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | AED 1.2B | AED 35.8B | AED 1,542.67 | 0.46% down | 24% down | ||
| 28 | Legend BiotechLEGN · Health Care | AED 1.2B | AED 12.1B | AED 62.32 | 5.34% up | 42% down | ||
| 29 | CytokineticsCYTK · Health Care | AED 1.1B | AED 26.6B | AED 190.90 | 0.64% up | 20% down | ||
| 30 | TG TherapeuticsTGTX · Health Care | AED 902.1M | AED 35.2B | AED 232.67 | 1.03% up | 107% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | AED 818.6M | AED 18.2B | AED 104.67 | 2.33% up | 20% down | ||
| 32 | Dr. Reddy's LaboratoriesRDY · Health Care | AED 711.5M | AED 45.8B | AED 54.90 | 1.01% up | 5% up | ||
| 33 | Axsome TherapeuticsAXSM · Health Care | AED 689.5M | AED 26.2B | AED 498.87 | 0.08% down | 7% down | ||
| 34 | Rhythm PharmaceuticalsRYTM · Health Care | AED 397.3M | AED 29.4B | AED 423.99 | 0.99% down | 13% up | ||
| 35 | Definium TherapeuticsDFTX · Health Care | AED 149M | AED 14.8B | AED 108.23 | 0.31% up | 169% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6725 AED). 26 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceuticals rank first by total debt?
AbbVie (AED 247.9B), Pfizer (AED 238B) and Merck & Co (AED 181.1B) are the top three of the 35 pharmaceuticals ranked by total debt as of 18 Nov 2026, 14:43 UTC.
How many pharmaceuticals are in this ranking?
35 are ranked by total debt. 26 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 35 pharmaceuticals ranked by total debt have a combined market value of AED 18.91T as of 18 Nov 2026, 14:43 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.